Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT02026934
NCT02026934No Longer AvailableNot Applicable

CliniMACS® CD34+ Reagent System for Expanded Access Use

Joseph Antin1 site in 1 countryStarted: March 2013Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
No Longer Available
Sponsor
Locations
1
Study OverviewEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

CliniMACs is an investigational device used to select and enrich stem cells. The device will select the stem cells with CD34+ protein. The participant will be infused with the CD34+ selected cells in the hopes that it will help the participant engraft. Engraftment is when transplanted stem cells resume production of healthy blood cells.

Detailed Description

  • After the screening procedures confirm that the participant is eligible to participate in the research study: If the participant takes part in this research study, the participant (and their donor) will have the following tests and procedures:
  • Donor Graft Collection: The participant's cell donor will undergo stem cell collection. The cells collected will be sent to the laboratory for processing.
  • Donor Graft Processing: In the laboratory the CliniMACS device will be used to separate the CD34+ stem cells from the other types of cells in the graft. After completing the necessary safety tests, the CD34+ selected donor graft will be ready for administration.
  • Donor Graft Infusion: The CD34+ selected donor graft will be infused through an intravenous (I.V.) catheter. The day of this infusion is called Day 0.
  • Follow-Up Visits: Approximately 3, 6 and 12 months after the donor graft infusion, the participant will return to clinic for follow-up visits. At each of the visits, the participant will have a physical exam and asked questions about your general health. The participant will also have routine blood tests performed (approximately 1 tablespoon of blood).
  • At times more cells are collected from a donation than are needed to do the transplantation. If your physician determines that it is preferable to administer a dose of cells that is less than the complete collection, the extra cells may be frozen and stored in our freezers for the participant's future use. If the cell counts do not improve, the participant will be given the remaining cells through an intravenous (I.V.) catheter.

Study Design

Study Type
Expanded Access

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patients aged >18 years
  • •Diagnosis is graft exhaustion.
  • •Ability to understand and willingness to sign a written informed consent document
  • •Matched related or unrelated donor must consent to provide an allograft.

Exclusion Criteria

  • •Symptomatic or uncontrolled cardiac failure or coronary artery disease.
  • •Karnofsky performance status < 60%.

Investigators

Sponsor
Joseph Antin
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Joseph Antin

Sponsor/Co-Investigator

Dana-Farber Cancer Institute

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
CD34+ Cell Enriched and T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Mismatched Related Donors or Borderline Organ FunctionMalignant DiseasesNon-malignant Diseases
NCT02162511Rajni Agarwal3
Terminated
Phase 2
T-cell Depleted Alternative Donor TransplantationChronic Myeloid LeukemiaLymphomasBone Marrow FailureHemoglobinopathyImmune DeficiencyAcute Myeloid LeukemiaMyelodysplastic SyndromeOsteopetrosisAcute Lymphoblastic Leukemia
NCT00968864Wake Forest University Health Sciences53
Available
Not Applicable
Treatment Use of the CliniMACS® CD34 TCR Alpha/Beta for Allogenic Transplant (Expanded Access Use)Transplant-Related DisorderGVH - Graft Versus Host Reaction
NCT06393660Victor Aquino
Withdrawn
Not Applicable
Donor Stem Cell Boost in Treating Patients With Low Blood Cells After Donor Stem Cell TransplantHematopoietic/Lymphoid CancerNeutropeniaAnemiaLymphopeniaThrombocytopenia
NCT01660347Sidney Kimmel Cancer Center at Thomas Jefferson University
Recruiting
Not Applicable
Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and GranulocytesGranulomaGranulomatous Disease, ChronicLeukocyte DiseaseGenetic Disease, X-LinkedGenetic Disease, Inborn
NCT00001405National Institute of Allergy and Infectious Diseases (NIAID)850